Livisto Listed by Deadlock Ransomware Group: Ransomware Claim — What’s Alleged & What To Do

Lede paragraph one: Ransomware operations continue to target organisations holding sensitive operational and commercial data across multiple sectors. On July 10 2026 the Deadlock group listed Livisto on its leak site, stating that internal files had been exfiltrated during a ransomware attack. Public information on the number of individuals affected or the precise contents of those files remains unavailable. Lede paragraph two: Livisto is described as an international pharmaceutical company focused on the veterinary market. The incident illustrates the ongoing exposure of such entities to data-exfiltration claims by ransomware actors, with limited verified detail released so far.

What happened

The listing appeared on July 10 2026. The only confirmed detail is that the group claims internal files were taken during a ransomware incident. No figure for records involved, no timeline for the intrusion itself, and no confirmation of subsequent publication or sale of data have been made public.

The group behind it: Deadlock

Deadlock is a ransomware actor that maintains a leak site to publicise claimed victims. Groups of this type typically gain initial access through common vectors such as compromised remote-access services or supply-chain weaknesses, then move laterally before deploying encryption and exfiltrating material. Prior activity attributed to Deadlock has included claims against entities in manufacturing, logistics and professional services, though each listing remains an unverified assertion until corroborated by the victim or independent investigation.

Livisto and its sector

Livisto operates as an international pharmaceutical company with a focus on veterinary products. Organisations in this sector routinely manage research data, manufacturing records, regulatory submissions and commercial agreements. A claim of file exfiltration therefore raises questions about the handling of proprietary and compliance-related information even when the exact scope stays undisclosed.

What was likely exposed

The reported information states only that internal files were exfiltrated. No inventory of document types, no confirmation of personal data, and no indication of customer or employee records have been released. In the absence of further disclosure it is not possible to determine whether any particular category of information left the organisation.

Why it matters

Pharmaceutical and veterinary companies hold material that can affect supply chains, regulatory compliance and commercial relationships. Even without confirmed personal-data exposure, the loss of internal files can create operational friction and regulatory scrutiny. Individuals connected to the company through employment, partnerships or product use have no public mechanism at present to assess whether their information was among the claimed files.

What to do if you're exposed

Monitor official statements from Livisto for any further detail on the incident. Review account statements and correspondence for unusual activity. Enable or strengthen multi-factor authentication on any services linked to the organisation. Consider the following immediate steps:

• Change passwords for any accounts that may share credentials with Livisto systems.
• Request data-breach notifications directly from the company if you hold a customer or partner relationship.
• Run a free exposure scan of your email address against known breach datasets to check for prior appearances of your information.

AICompiled with AI assistance from public sources and published under our editorial standards.